BioSymetrics
AI platform for life sciences that standardizes and analyzes biomedical data to accelerate drug development decisions.
What it does
BioSymetrics is an AI platform for pharmaceutical and biotech companies that addresses the fundamental data problem in drug development - clinical and biomedical data is collected in inconsistent formats, across incompatible systems, making cross-study analysis extremely difficult. BioSymetrics' AI harmonizes data from disparate clinical trials, genomic studies, and real-world evidence sources into a unified, analysis-ready format - enabling drug developers to run AI models across datasets that were previously incompatible. AI capabilities include automated data standardization and CDISC harmonization, AI-powered biomarker discovery that identifies patient subpopulations most likely to respond to a drug, and machine learning models that predict clinical trial outcomes from early biomarker and safety signals.
Why AI-NATIVE
BioSymetrics is AI-native - automated biomedical data harmonization at scale and AI-driven biomarker discovery from harmonized multi-study datasets are the core product capabilities.
Best for
Pharmaceutical companies and biotech firms use BioSymetrics to unlock value from their clinical data assets - AI harmonization enabling cross-trial analysis and biomarker discovery that drives more informed development decisions.
Limitations
BioSymetrics is purpose-built for pharmaceutical and clinical data — companies outside the life sciences space have no applicable use case for biomedical data harmonization and biomarker discovery.
BioSymetrics' AI delivers the most insight when applied to large, rich clinical datasets — companies with limited clinical data history or poorly documented historical studies see reduced analytical value.
BioSymetrics surfaces biomarker patterns and data insights but drug development decisions based on those insights require specialized biostatisticians and clinical scientists — the platform amplifies expert teams rather than replacing them.
Alternatives by segment
| If you need… | Consider instead |
|---|---|
| Clinical trial data management platform | Medidata |
| AI drug discovery platform | BenevolentAI |
| Genomics research platform | Benchling |
BioSymetrics enterprise contracts not published. Priced based on data volume, study count, and analytical scope. Annual SaaS contracts with implementation.
